Core Viewpoint - The approval of the clinical trial for DCTY0801 injection marks a significant milestone in the product development process for the company, enhancing its competitiveness in the oncology treatment sector [1] Group 1 - The company's subsidiary, Beijing Dingcheng Peptide Source Biotechnology Co., Ltd., received the clinical trial approval notice from the National Medical Products Administration [1] - The drug DCTY0801 is indicated for EGFRvIII positive recurrent or progressive high-grade glioma [1] - This clinical trial approval is expected to accelerate the progress of the company's research and development products [1]